Literature DB >> 33547925

Urinary stone disease prevalence and associations in cystic fibrosis.

Jonathan B Zuckerman1, Eric N Taylor2,3, Jeremy F Wright4, Wendy Y Craig5, F L Lucas5, David S Goldfarb6.   

Abstract

Cystic fibrosis (CF) may predispose patients to urinary stone disease (USD), but reported prevalence of USD in patients with CF in previous small studies is variable. To date, analysis of risk factors for USD within the CF population has been limited. We studied 29,396 patients in the Cystic Fibrosis Foundation Patient Registry to calculate age and sex-stratified prevalence of USD. For adult patients, we examined age and multivariable-adjusted cross-sectional associations between demographic and clinical factors, CFTR mutation class, and prevalent USD. Prevalence of USD was 0.4% (95% CI 0.3-0.5%) under age 18 years, 3.1% (2.7-3.6%) at 18-24 years, 6.4% (5.8-7.1%) at 25-34 years, 7.5% (6.5-8.5%) at 35-44 years, and 6.7% (5.8-7.8%) at 45 years and older. Prevalence for women was higher than men at younger (< 45 years) but not older ages (P value for interaction < 0.0005). Multivariable odds of prevalent USD were significantly increased for severe CFTR mutations, OR 1.53 (1.14-2.06), diabetes, OR 1.24 (1.03-1.50), hypertension, OR 1.58 (1.29-1.93), and chronic macrolide therapy, OR 1.27 (1.07-1.52). BMI was not associated with USD. USD prevalence in CF is similar to that in the general population. With the exception of BMI, known risk factors for USD in the general population also appear to be important for patients with CF. We identified several novel associations in CF patients, including greater prevalence of USD in individuals with severe CFTR mutations and among young women.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Cystic fibrosis; Epidemiology; Risk factors; Urolithiasis

Mesh:

Substances:

Year:  2021        PMID: 33547925     DOI: 10.1007/s00240-021-01244-8

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  12 in total

1.  Cystic fibrosis.

Authors:  Steven M Rowe; Stacey Miller; Eric J Sorscher
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

2.  Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis.

Authors:  Hansjosef Böhles; Boris Gebhardt; Thomas Beeg; Adrian C Sewell; Eivind Solem; Georg Posselt
Journal:  J Pediatr       Date:  2002-01       Impact factor: 4.406

3.  Time trends in reported prevalence of kidney stones in the United States: 1976-1994.

Authors:  Kiriaki K Stamatelou; Mildred E Francis; Camille A Jones; Leroy M Nyberg; Gary C Curhan
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

4.  Renal diseases in adults with cystic fibrosis: a 40 year single centre experience.

Authors:  M J Wilcock; A Ruddick; K M Gyi; M E Hodson
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

5.  Prevalence of kidney stones in the United States.

Authors:  Charles D Scales; Alexandria C Smith; Janet M Hanley; Christopher S Saigal
Journal:  Eur Urol       Date:  2012-03-31       Impact factor: 20.096

6.  The role of Oxalobacter formigenes colonization in calcium oxalate stone disease.

Authors:  Roswitha Siener; Ursula Bangen; Harmeet Sidhu; Ruth Hönow; Gerd von Unruh; Albrecht Hesse
Journal:  Kidney Int       Date:  2013-03-27       Impact factor: 10.612

7.  Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria.

Authors:  H Sidhu; B Hoppe; A Hesse; K Tenbrock; S Brömme; E Rietschel; A B Peck
Journal:  Lancet       Date:  1998-09-26       Impact factor: 79.321

8.  Loss of Cystic Fibrosis Transmembrane Regulator Impairs Intestinal Oxalate Secretion.

Authors:  Felix Knauf; Robert B Thomson; John F Heneghan; Zhirong Jiang; Adedotun Adebamiro; Claire L Thomson; Christina Barone; John R Asplin; Marie E Egan; Seth L Alper; Peter S Aronson
Journal:  J Am Soc Nephrol       Date:  2016-06-16       Impact factor: 10.121

9.  The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

Authors:  Emily A Knapp; Aliza K Fink; Christopher H Goss; Ase Sewall; Josh Ostrenga; Christopher Dowd; Alexander Elbert; Kristofer M Petren; Bruce C Marshall
Journal:  Ann Am Thorac Soc       Date:  2016-07

10.  Cystic fibrosis and calcium oxalate nephrolithiasis.

Authors:  A S Chidekel; T F Dolan
Journal:  Yale J Biol Med       Date:  1996 Jul-Aug
View more
  1 in total

1.  Association Study Between Polymorphic Loci in Cholesterol Metabolism Pathway and Gallstone in the Tibetan Population.

Authors:  Lifeng Ma; Hui Chen; Zhiying Zhang; Lijun Liu; Yiduo Zhao; Yansong Li; Zhipeng Zhao; Haitao Chen; Longli Kang
Journal:  Front Genet       Date:  2022-05-16       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.